Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response

NCT04205552 is registered in ClinicalTrials.gov with University Hospital, Essen as lead sponsor.

NCT NCT04205552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological Response
Lead sponsor
University Hospital, Essen
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2020
Completion date
November 27, 2025
Enrollment
90 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage ii, nsclc, stage i, nsclc, stage iiia